West Pharmaceutical Services raises 2026 sales guidance after Q3 results

West Pharmaceutical Services reported third quarter 2026 sales of USD 874.5m and net income of USD 214m. The maker of pharmaceutical packaging and delivery components raised its full year 2026 net sales guidance to USD 3.41bn-3.42bn, with diluted EPS guidance of USD 9.31-9.41, and lifted its fourth quarter dividend. The company also completed USD 685.26m of share repurchases under its 2026 buyback programme.

Why this mattersRaised full-year guidance at a leading maker of pharmaceutical packaging and delivery components indicates firm demand from drug producers for its containment products.

• Q3 2026 sales were USD 874.5m with net income of USD 214m
• Full year 2026 net sales guidance raised to USD 3.41bn-3.42bn
• Diluted EPS guidance raised to USD 9.31-9.41
• The company completed USD 685.26m of share repurchases under its 2026 buyback programme
• A higher fourth quarter dividend was announced alongside the guidance increase
• Nine month 2026 revenue was USD 2.59bn and net income USD 506.8m

Relevant to you? Yes No